Condition: Type 1 Diabetes · Diabetes Mellitus, Type 1 · Sponsor: Creative Medical Technology Holdings Inc
The brief purpose of this research study is to learn about the safety and efficacy of intra-arterial administration of CELZ-201 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D).
This description comes directly from the study's public registry record.
Creative Medical Technology · (702) 588-1890 · clinicaltrials@creativemedicaltechnology.com
Always discuss trial participation with your own doctor first.
| Diabetes Research Institute, University of Miami Miller School of Medicine | Miami, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05626712